Guidant releases one-year DES data
This article was originally published in The Gray Sheet
Executive Summary
Angiographic in-stent late loss and in-segment late loss with Guidant's Xience V everolimus-eluting stent are 72% and 78% lower than with Guidant's bare metal Multi-Link Vision, according to 12-month results from the firm's SPIRIT FIRST feasibility trial. Xience V showed a device-related major adverse cardiac event rate of 3.8% (1/26) compared with 21.4% (6/28) in the control arm. Xience V is also being measured against Boston Scientific's Taxus paclitaxel-eluting stent in two ongoing European trials (1"The Gray Sheet" Sept. 26, 2005, In Brief)...